[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614753":3},{"organization":4,"outcomesModule":7,"designInfo":19,"detailedDescription":18,"studyPopulation":18,"armGroups":25,"interventions":34,"overallOfficials":48,"centralContacts":53,"locations":58,"responsibleParty":75,"collaborators":18,"id":78,"slug":18,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":18,"eligibilityCriteria":83,"healthyVolunteers":79,"sex":84,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":18,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":61,"whyStopped":18,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"RenJi Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":18},[9],{"measure":10,"description":11,"timeFrame":12},"Proportion of patients with pCR","Number of patients with pathological complete response\u002FNumber of all eligible patients","1-2 weeks after surgery",[14],{"measure":15,"description":16,"timeFrame":17},"Proportion of patients with adverse events","Number of patients with adverse events during neoadjuvant therapy assessed according to the NCI CTCAE v5.0\u002FNumber of all eligible patients","From the date of starting neoadjuvant therapy to the end of the treatment (up to approximately 1 year)",null,{"allocation":20,"interventionModel":21,"interventionModelDescription":18,"primaryPurpose":22,"observationalModel":18,"timePerspective":18,"maskingInfo":23},"NA","SINGLE_GROUP","TREATMENT",{"masking":24,"maskingDescription":18,"whoMasked":18},"NONE",[26],{"label":27,"type":28,"description":29,"interventionNames":30},"neoadjuvant serplulimab","EXPERIMENTAL","serplulimab in combination with weekly paclitaxel and carboplatin as neoadjuvant therapy",[31,32,33],"Drug: Serplulimab","Drug: Paclitaxel","Drug: Carboplatin",[35,40,44],{"type":36,"name":37,"description":38,"armGroupLabels":39,"otherNames":18},"DRUG","Serplulimab","1.5mg\u002Fkg qw, start from C1D15",[27],{"type":36,"name":41,"description":42,"armGroupLabels":43,"otherNames":18},"Paclitaxel","80mg\u002Fm\\^2 qw",[27],{"type":36,"name":45,"description":46,"armGroupLabels":47,"otherNames":18},"Carboplatin","AUC=1.5, D1, 8, 15, every 28 days",[27],[49],{"name":50,"affiliation":51,"role":52},"Wenjin Yin, M.D.","Renji Hospital,School of Medicine, Shanghai Jiaotong University","PRINCIPAL_INVESTIGATOR",[54],{"name":50,"role":55,"phone":56,"phoneExt":18,"email":57},"CONTACT","86(21)68385569","yinwenjin@renji.com",[59],{"facility":60,"status":61,"city":62,"state":18,"zip":63,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":71,"contacts":72},"Renji Hospital, School of Medicine, Shanghai Jiaotong University","RECRUITING","Shanghai","200127","China","CN",{"type":67,"coordinates":68},"Point",[69,70],121.45806,31.22222,{"lat":70,"lon":69},[73],{"name":50,"role":55,"phone":74,"phoneExt":18,"email":57},"86(21)58852345",{"type":52,"investigatorFullName":76,"investigatorTitle":77,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Wenjin Yin","Deputy Chief of Breast Surgery Department","100614753",false,"NCT07283692","Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)","NEOadjuvant SERplulimab Plus Weekly PaclitaxEl and carboplatiN in Triple-negative Breast Cancer: a Prospective, Single-arm, Multicenter, Phase 2 Clinical Trial","Inclusion Criteria:\n\n* Female, Aged ≥18 and ≤70 years\n* Histologically confirmed triple negative breast cancer (ER\\\u003C10%, PR\\\u003C10%, and HER2 negative)\n* Subjects with at least one evaluable lesion\n* ECOG 0-1\n* Adequate organ function\n\nExclusion Criteria:\n\n* Metastatic disease (Stage IV)\n* Female patients who are pregnancy, lactation or women who are of childbearing potential tested positive in baseline pregnancy test;Female patients of childbearing age that are reluctant to take effective contraceptive measures throughout the trial period","FEMALE","18 Years","70 Years",{"count":88,"type":89},46,"ESTIMATED","INTERVENTIONAL",[92],"PHASE2","This is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant serplulimab plus weekly paclitaxel and carboplatin in patients with triple-negative breast cancer.",[95],"Triple Negative Breast Cancer",[97,98,99],"breast cancer","neoadjuvant","serplulimab","2026-05-10",{"date":102,"type":103},"2026-05-13","ACTUAL",{"date":105,"type":103},"2026-03-01",{"date":107,"type":89},"2031-09",{"name":5,"class":6},1]